questionsmedicales.fr
Composés chimiques organiques
Hydrocarbures
Hydrocarbures cycliques
Hydrocarbures aromatiques
Dérivés du benzène
Phénols
Catéchols
Masoprocol
Masoprocol : Questions médicales fréquentes
Termes MeSH sélectionnés :
Microsatellite Instability
Diagnostic
2
Masoprocol
Diagnostic médical
Essais cliniques
Évaluation des symptômes
Symptômes
2
Inflammation
Cancer de la peau
Effets secondaires
Irritation cutanée
Prévention
2
Prévention des maladies
Traitement
Prévention
Exposition au soleil
Traitements
2
Traitement topique
Lésions cutanées
Administration locale
Crème
Complications
2
Complications
Infections cutanées
Interactions médicamenteuses
Consultation médicale
Facteurs de risque
2
Facteurs de risque
Allergies cutanées
Immunodépression
Surveillance médicale
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Masoprocol : Questions médicales les plus fréquentes",
"headline": "Masoprocol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Masoprocol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-01",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Masoprocol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Catéchols",
"url": "https://questionsmedicales.fr/mesh/D002396",
"about": {
"@type": "MedicalCondition",
"name": "Catéchols",
"code": {
"@type": "MedicalCode",
"code": "D002396",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.455.426.559.389.657.166"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Masoprocol",
"alternateName": "Masoprocol",
"code": {
"@type": "MedicalCode",
"code": "D009637",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mohammed Baqur S Al-Shuhaib",
"url": "https://questionsmedicales.fr/author/Mohammed%20Baqur%20S%20Al-Shuhaib",
"affiliation": {
"@type": "Organization",
"name": "Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Sarfaraz Alam",
"url": "https://questionsmedicales.fr/author/Sarfaraz%20Alam",
"affiliation": {
"@type": "Organization",
"name": "Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland."
}
},
{
"@type": "Person",
"name": "Salman Ali Khan",
"url": "https://questionsmedicales.fr/author/Salman%20Ali%20Khan",
"affiliation": {
"@type": "Organization",
"name": "Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan."
}
},
{
"@type": "Person",
"name": "Hayder O Hashim",
"url": "https://questionsmedicales.fr/author/Hayder%20O%20Hashim",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Daniel H Obayes",
"url": "https://questionsmedicales.fr/author/Daniel%20H%20Obayes",
"affiliation": {
"@type": "Organization",
"name": "College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Genomic instability and the link to infertility: A focus on microsatellites and genomic instability syndromes.",
"datePublished": "2022-06-03",
"url": "https://questionsmedicales.fr/article/35671666",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejogrb.2022.06.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Microsatellite Instability in Russian Patients with Colorectal Cancer.",
"datePublished": "2022-06-25",
"url": "https://questionsmedicales.fr/article/35806077",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23137062"
}
},
{
"@type": "ScholarlyArticle",
"name": "Noninvasive detection of microsatellite instability in patients with endometrial cancer.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36650670",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijc.34435"
}
},
{
"@type": "ScholarlyArticle",
"name": "PAIP 2020: Microsatellite instability prediction in colorectal cancer.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37494811",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.media.2023.102886"
}
},
{
"@type": "ScholarlyArticle",
"name": "Microsatellite Instability and Aberrant Pre-mRNA Splicing: How Intimate Is It?",
"datePublished": "2023-01-25",
"url": "https://questionsmedicales.fr/article/36833239",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes14020311"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures",
"item": "https://questionsmedicales.fr/mesh/D006838"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrocarbures cycliques",
"item": "https://questionsmedicales.fr/mesh/D006844"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hydrocarbures aromatiques",
"item": "https://questionsmedicales.fr/mesh/D006841"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dérivés du benzène",
"item": "https://questionsmedicales.fr/mesh/D001555"
},
{
"@type": "ListItem",
"position": 7,
"name": "Phénols",
"item": "https://questionsmedicales.fr/mesh/D010636"
},
{
"@type": "ListItem",
"position": 8,
"name": "Catéchols",
"item": "https://questionsmedicales.fr/mesh/D002396"
},
{
"@type": "ListItem",
"position": 9,
"name": "Masoprocol",
"item": "https://questionsmedicales.fr/mesh/D009637"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Masoprocol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Masoprocol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Masoprocol",
"description": "Comment le masoprocol est-il diagnostiqué ?\nQuels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Microsatellite+Instability#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Masoprocol",
"description": "Quels symptômes le masoprocol peut-il traiter ?\nLe masoprocol provoque-t-il des effets secondaires ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Microsatellite+Instability#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Masoprocol",
"description": "Le masoprocol peut-il prévenir des maladies ?\nQuelles mesures préventives sont recommandées avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Microsatellite+Instability#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Masoprocol",
"description": "Dans quel type de traitement le masoprocol est-il utilisé ?\nComment le masoprocol est-il administré ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Microsatellite+Instability#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Masoprocol",
"description": "Quelles complications peuvent survenir avec le masoprocol ?\nLe masoprocol peut-il interagir avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Microsatellite+Instability#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Masoprocol",
"description": "Qui est à risque d'effets secondaires du masoprocol ?\nY a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Microsatellite+Instability#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le masoprocol est-il diagnostiqué ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le masoprocol n'est pas diagnostiqué, mais utilisé dans le traitement de certaines conditions."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests cliniques et des évaluations de symptômes sont utilisés pour mesurer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes le masoprocol peut-il traiter ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour traiter l'inflammation et certains types de cancers cutanés."
}
},
{
"@type": "Question",
"name": "Le masoprocol provoque-t-il des effets secondaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des irritations cutanées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'est pas utilisé pour la prévention, mais pour le traitement des maladies existantes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives sont recommandées avec le masoprocol ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition excessive au soleil et suivre les conseils médicaux."
}
},
{
"@type": "Question",
"name": "Dans quel type de traitement le masoprocol est-il utilisé ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé dans le traitement topique des lésions cutanées et des cancers cutanés."
}
},
{
"@type": "Question",
"name": "Comment le masoprocol est-il administré ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement appliqué localement sous forme de crème ou de gel."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le masoprocol ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections cutanées peuvent survenir en cas d'irritation."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il interagir avec d'autres médicaments ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut interagir avec certains médicaments, il est donc important de consulter un médecin."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires du masoprocol ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant une peau sensible ou des antécédents d'allergies cutanées sont à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients immunodéprimés doivent être surveillés de près lors de l'utilisation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/03/2025
Contenu vérifié selon les dernières recommandations médicales
1 publication dans cette catégorie
Affiliations :
Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :
Infertility is associated to multiple types of different genomic instabilities and is a genetic feature of genomic instability syndromes. While the mismatch repair machinery contributes to the mainten...
The aim of this study was to determine the characteristics of Russian patients with microsatellite instability (MSI) tumors. MSI in the tumor was determined in 514 patients with colon cancer using PCR...
The analysis of mismatch repair proteins in solid tissue is the standard of care (SoC) for the microsatellite instability (MSI) characterization in endometrial cancer (EC). Uterine aspirates (UAs) or ...
Microsatellite instability (MSI) refers to alterations in the length of simple repetitive genomic sequences. MSI status serves as a prognostic and predictive factor in colorectal cancer. The MSI-high ...
Cancers that belong to the microsatellite instability (MSI) class can account for up to 15% of all cancers of the digestive tract. These cancers are characterized by inactivation, through the mutation...
Here, we determined the frequency of microsatellite instability (MSI) and the impact of MSI-high (MSI-H) on clinical outcomes of Thai patients with endometrial cancer (EC). Tissue samples of 110 Thai ...
Lynch syndrome (LS) is characterized by germline mutations in the DNA mismatch repair (MMR) genes. In colorectal cancer (CRC), germline mutations of DNA MMR genes commonly lead to microsatellite insta...
The purpose of the current study was to determine whether there is a difference between high levels of microsatellite instability (MSI-H) and microsatellite stability (MSS) in DNA mismatch repair-defi...
A total of 452 CRC patients with DMMR from December, 2014, to April, 2021, in our hospital were selected retrospectively. However, only 105 patients underwent Sanger or next-generation-sequencing (NGS...
The MSS group was associated with a higher mutation rate in the KRAS gene (...
The MSI-H status was associated with colon cancer and a lower mutation rate of the KRAS gene in DMMR patients. In CRC-DMMR patients, the MSS group exhibited better OS and DFS than the MSI-H group, alt...
Colon adenocarcinoma (COAD) is a prevalent malignancy that causes significant mortality. Microsatellite instability plays a pivotal function in COAD development and immunotherapy resistance. However, ...
CIBERSORT and ESTIMATE analyses were performed to evaluate immune infiltration in COAD samples, followed by correlation analysis for MSI and immune infiltration. Then, differentially expressed genes (...
In total, 701 significant DEGs related to MSI status were identified, and WGCNA revealed two modules associated with the immune score. Then, a seven-gene prognostic model was constructed using LASSO a...
The seven-gene prognostic model constructed could predict the survival of COAD and ICI response and serve as a reference for immunotherapy decisions....
Since US Food and Drug Administration approval of programmed death ligand 1 (PD-L1) as the first companion diagnostic for immune checkpoint inhibitors (ICIs) in non-small cell lung cancer, many patien...